Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $5.5 million.

  • Rhythm Pharmaceuticals' Cost of Revenue rose 4365.2% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year increase of 4418.26%. This contributed to the annual value of $13.4 million for FY2024, which is 4371.1% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Cost of Revenue is $5.5 million, which was up 4365.2% from $5.5 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Cost of Revenue peaked at $5.5 million during Q2 2025, and registered a low of $4000.0 during Q1 2021.
  • In the last 5 years, Rhythm Pharmaceuticals' Cost of Revenue had a median value of $2.2 million in 2023 and averaged $2.1 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Cost of Revenue skyrocketed by 565000.0% in 2022 and then soared by 1713.58% in 2024.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Cost of Revenue stood at $236000.0 in 2021, then soared by 335.59% to $1.0 million in 2022, then soared by 214.49% to $3.2 million in 2023, then grew by 17.14% to $3.8 million in 2024, then soared by 45.21% to $5.5 million in 2025.
  • Its Cost of Revenue was $5.5 million in Q3 2025, compared to $5.5 million in Q2 2025 and $3.6 million in Q1 2025.